Gebre M, Nomburg JL, Gewurz BE. CRISPR-Cas9 Genetic Analysis of Virus-Host Interactions. Viruses. 2018;10(2). doi:10.3390/v10020055
Rehm HL. Evolving health care through personal genomics. Nat Rev Genet. 2017;18(4):259-267. doi:10.1038/nrg.2016.162
Habeb AM, Flanagan SE, Zulali MA, et al. Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome. Diabetologia. 2018;61(5):1027-1036. doi:10.1007/s00125-018-4554-x
Holm IA, Yu TW, Joffe S. From Sequence Data to Returnable Results: Ethical Issues in Variant Calling and Interpretation. Genet Test Mol Biomarkers. 2017;21(3):178-183. doi:10.1089/gtmb.2016.0413
Landry LG, Rehm HL. Association of Racial/Ethnic Categories With the Ability of Genetic Tests to Detect a Cause of Cardiomyopathy. JAMA Cardiol. 2018;3(4):341-345. doi:10.1001/jamacardio.2017.5333
Nielsen DE, Carere DA, Wang C, Roberts S, Green RC, PGen Study Group. Diet and exercise changes following direct-to-consumer personal genomic testing. BMC Med Genomics. 2017;10(1):24. doi:10.1186/s12920-017-0258-1
Wang G, Chow RD, Ye L, et al. Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv. 2018;4(2):eaao5508. doi:10.1126/sciadv.aao5508
Van Allen EM. The Potential and Challenges of Expanded Germline Testing in Clinical Oncology. JAMA. 2017;318(9):801-803. doi:10.1001/jama.2017.11022
Christensen KD, Vassy JL, Phillips KA, et al. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018;20(12):1544-1553. doi:10.1038/gim.2018.35
Cirino AL, Lakdawala NK, McDonough B, et al. A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circ Cardiovasc Genet. 2017;10(5). doi:10.1161/CIRCGENETICS.117.001768